468 related articles for article (PubMed ID: 10445400)
1. Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity.
Lewis DF
Exp Toxicol Pathol; 1999 Jul; 51(4-5):369-74. PubMed ID: 10445400
[TBL] [Abstract][Full Text] [Related]
2. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.
Lewis DF
Xenobiotica; 2002 Apr; 32(4):305-23. PubMed ID: 12028664
[TBL] [Abstract][Full Text] [Related]
3. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
Lewis DF
Arch Biochem Biophys; 2003 Jan; 409(1):32-44. PubMed ID: 12464242
[TBL] [Abstract][Full Text] [Related]
4. Human cytochrome P450s: selectivity and measurement in vivo.
Smith DA; Abel SM; Hyland R; Jones BC
Xenobiotica; 1998 Dec; 28(12):1095-128. PubMed ID: 9890156
[No Abstract] [Full Text] [Related]
5. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
7. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
[TBL] [Abstract][Full Text] [Related]
8. Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily.
Lewis DF; Ito Y; Goldfarb PS
Curr Drug Metab; 2006 Aug; 7(6):589-98. PubMed ID: 16918314
[TBL] [Abstract][Full Text] [Related]
9. Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases.
Johnson EF; Stout CD
Biochem Biophys Res Commun; 2005 Dec; 338(1):331-6. PubMed ID: 16157296
[TBL] [Abstract][Full Text] [Related]
10. Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism.
Lewis DF; Lake BG; Dickins M
Drug Metabol Drug Interact; 2004; 20(3):111-42. PubMed ID: 15508429
[TBL] [Abstract][Full Text] [Related]
11. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA.
Ridderström M; Zamora I; Fjellström O; Andersson TB
J Med Chem; 2001 Nov; 44(24):4072-81. PubMed ID: 11708911
[TBL] [Abstract][Full Text] [Related]
12. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
[TBL] [Abstract][Full Text] [Related]
13. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
[TBL] [Abstract][Full Text] [Related]
14. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
15. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples.
Boobis AR; McKillop D; Robinson DT; Adams DA; McCormick DJ
Xenobiotica; 1998 May; 28(5):493-506. PubMed ID: 9622851
[TBL] [Abstract][Full Text] [Related]
16. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.
Lewis DF; Lake BG; George SG; Dickins M; Eddershaw PJ; Tarbit MH; Beresford AP; Goldfarb PS; Guengerich FP
Toxicology; 1999 Nov; 139(1-2):53-79. PubMed ID: 10614688
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
19. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity.
Lewis DF; Dickins M; Lake BG; Eddershaw PJ; Tarbit MH; Goldfarb PS
Toxicology; 1999 Mar; 133(1):1-33. PubMed ID: 10413191
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
